Digestive Disease Week (DDW 2023)

  • 06-09 May 2023
  • Chicago, IL, United States(Hybrid)


Digestive Disease Week (DDW 2023) is a conference that covers topics such as:

  • Liver disease
  • Diagnosis and treatment of gastrointestinal tract and liver disorders
  • Diseases and functions of the alimentary tract
  • Gastrointestinal Endoscopy

Digestive Disease Week (DDW 2023) brings together researchers and physicians in the fields of hepatology, gastroenterology, gastrointestinal surgery and endoscopy.

Digestive Disease Week (DDW 2023) will be held in Chicago as well as online on 06-09 May 2023.


  • Chicago, Illinois, United States

More Details

0-285 US Dollar (Estimated)
AGA Institute - American Gastroenterological Association

Future Events

Past Events


Please, check the official event website for possible changes, before making any traveling arrangements

Event Categories

Health & Medicine: Gastroenterology, Hepatology

Other Events with Similar Categories

Other Events with Similar Location or Organizer

Featured Conferences & Exhibitions

Articles / News / Press releases

Article content. Press on the above link to close

Backgrounds: Angiogenesis plays an important role in the development of liver fibrosis and portal hypertension. Long non-coding RNAs (lncRNAs) are involved in the liver diseases and angiogenesis.

Objective: This study aimed to investigate the effect of lncRNA-COX-2 in the progress of liver fibrosis, and the underlying mechanisms were also studied.

Methods: Thirty-six SPF Bal B/C mice were randomly assigned into 3 groups with 12 mice in each group. The control group received injection of normal saline (100 µl, twice a week); the CCl4-2M group given intraperitoneal injection of carbon tetrachloride (CCl4) for 2 months; the CCl4-3M group given intraperitoneal injection of CCl4 for 3 months. The hepatic fibrosis was assessed by the hepatic fibrotic areas. Quantitative real-time PCR was performed to evaluate the expressions of lncRNA-COX-2 and COX-2 in the liver tissue, and immunohistochemistry staining was used to detect COX-2 in the liver tissue. Correlation of lncRNA-COX-2 and COX-2 with liver fibrotic areas was completed by using Pearson correlation analysis. In vitro, the EOMA endothelial cells were treated with lipopolysaccharide (LPS) for 6 hours, and lncRNA-COX-2, COX-2, VEGF and VEGFR-2 were evaluated by quantitative real-time PCR and immunohistochemistry staining.


Extensive nodular formation was observed in the liver after the treatment with CCl4. Compared with the control group, fibrotic areas of liver tissues in the CCl4-2M group and CCl4-3M group were increased by 4 times and 9 times, respectively. The CD31 positive areas and vascular areas were significantly increased in cirrhotic livers. Additionally, up-regulations of COX-2 mRNA and COX-2 protein were observed in both the CCl4-2M group and the CCl4-3M group, compared with the control group. Moreover, the level of lncRNA-COX-2 in the CCl4-2M group and CCl4-3M group were nearly 2 times higher than that in the control group. Meanwhile, the expression of COX-2 and lncRNA-COX-2 were positively correlated with the liver fibrotic areas. (R=0.801, P<0.05; R=0.593, P<0.05). Besides, a positive correlation between the expression of COX-2 mRNA and lncRNA-COX-2 was  displayed in cirrhotic liver (R=0.667, P<0.05). And there also was a positive correlation between the CD31 positive areas and lncRNA-COX-2 in cirrhotic liver (R=0.605, P<0.05). In vitro, the gene expression of lncRNA-COX-2, COX-2, VEGF and VEGFR-2 were remarkably increased in LPS-treated EOMA cells. Consistently, the protein expression of COX-2 and VEGF were also obviously increased in LPS-treated EOMA cells.

Conclusions: Expressions of COX-2 and lncRNA-COX-2 increase in the progress of liver fibrosis. LncRNA-COX-2 may exacerbate liver fibrosis via increasing the inhtraheaptic angiogenesis. And the neoangiogenic effect of lncRNA-COX-2 may attribute to its up-regulation of COX-2, VEGF and VEGFR-2.